Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.

× No keyword cloud information.

21 in total

1. Incomplete cold antibodies role of complement in sensitization to antiglobulin serum by potentially haemolytic antibodies.

Authors: J V DACIE; J H CROOKSTON; W N CHRISTENSON
Journal: Br J Haematol Date: 1957-01 Impact factor: 6.998

2. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Authors: Mathias J Rummel; Salah E Al-Batran; Soo-Z Kim; Manfred Welslau; Ralf Hecker; Dorothea Kofahl-Krause; Klaus-M Josten; Heinz Dürk; Andreas Rost; Michael Neise; Ulrich von Grünhagen; Kai U Chow; Martin-L Hansmann; Dieter Hoelzer; Paris S Mitrou
Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544

3. Cold agglutinin disease.

Authors: Morie A Gertz
Journal: Haematologica Date: 2006-04 Impact factor: 9.941

4. Cold agglutinin hemolysis responding to fludarabine therapy.

Authors: A Jacobs
Journal: Am J Hematol Date: 1996-12 Impact factor: 10.047

Review 5. Rituximab therapy for autoimmune haematological diseases.

Authors: Wilma Barcellini; Alberto Zanella
Journal: Eur J Intern Med Date: 2011-01-31 Impact factor: 4.487

6. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors: Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal: Blood Date: 2004-10-19 Impact factor: 22.113

7. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.

Authors: D Machover; B Delmas-Marsalet; S C Misra; Y Gumus; E Goldschmidt; A Schilf; N Frénoy; J F Emile; B Debuire; C Guettier; P Farrokhi; B Boulefdaoui; F Norol; N Parquet; A Ulusakarya; C Jasmin
Journal: Ann Oncol Date: 2001-10 Impact factor: 32.976

Review 8. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.

Authors: Mathias J Rummel; Paris S Mitrou; Dieter Hoelzer
Journal: Semin Oncol Date: 2002-08 Impact factor: 4.929

9. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Authors: Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen; Henrik Hjorth-Hansen; Ruth Langholm; Håvar Knutsen; Waleed Ghanima; Fuad Victor Shammas; Geir E Tjønnfjord
Journal: Blood Date: 2003-12-30 Impact factor: 22.113

10. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre.

Authors: R J Sokol; S Hewitt; B K Stamps
Journal: Br Med J (Clin Res Ed) Date: 1981-06-20

5 in total

Review 1. Cold agglutinin disease.

Authors: Sigbjørn Berentsen
Journal: Hematology Am Soc Hematol Educ Program Date: 2016-12-02

2. Therapy for chronic cold agglutinin disease: perspective for further improvements.

Authors: Sigbjørn Berentsen
Journal: Blood Transfus Date: 2013-01-22 Impact factor: 3.443

Review 3. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.

Authors: Sigbjørn Berentsen; Tatjana Sundic
Journal: Biomed Res Int Date: 2015-01-29 Impact factor: 3.411

Review 4. Role of Complement in Autoimmune Hemolytic Anemia.

Authors: Sigbjørn Berentsen
Journal: Transfus Med Hemother Date: 2015-09-07 Impact factor: 3.747

5. Two cases of primary cold agglutinin disease associated with megaloblastic anemia.

Authors: Shinsaku Imashuku; Naoko Kudo; Katsushige Takagishi; Katsuyasu Saigo
Journal: Case Rep Hematol Date: 2015-03-30

5 in total